Literature DB >> 20683591

99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres.

Bieke Lambert1, Jeroen Mertens, Emiel J Sturm, Steven Stienaers, Luc Defreyne, Yves D'Asseler.   

Abstract

PURPOSE: 90Y microspheres are used for intra-arterial treatment of liver tumours. In the patient preparation, a hepatic angiogram is performed and all arteries that could transport microspheres from the targeted liver vasculature to extrahepatic organs are blocked. 99mTc-labelled macroaggregated albumin (MAA) is injected intra-arterially to simulate the treatment and whole-body scintigraphy and single photon emission computed tomography (SPECT) of the abdomen are performed.
METHODS: Various aspects of lung shunt fraction (LSF) estimation were studied: interobserver and intrapatient variability, influence of scan quality and underlying disease. Secondly, the interobserver variability in reading the MAA SPECT of the abdomen was investigated. We reviewed 90 whole-body scans and 20 SPECT scans performed at our institution. Readers were blinded to each other's findings. Scoring the scan quality was based on the visualization of tracer degradation.
RESULTS: The mean difference in LSF between the readers was 1%. In 1 of 23 patients who underwent repeated MAA injections a marked change in LSF was observed. No significant differences in LSF were recorded for primary versus secondary liver tumours. There was a correlation between scan quality and LSF, suggesting that low scan quality leads to overestimation of the LSF. Concordant results in ruling out the presence of extrahepatic tracer deposition were reached in 17 of 20 scans (85%).
CONCLUSION: Interobserver and intrapatient variability in LSF calculation was limited. LSF was clearly dependent on scan quality. The underlying disease had no significant impact on the LSF. Interobserver variability for reading the MAA SPECT scans was acceptable.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683591     DOI: 10.1007/s00259-010-1566-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  9 in total

1.  Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer.

Authors:  S Ho; W Y Lau; T W Leung; M Chan; P J Johnson; A K Li
Journal:  Eur J Nucl Med       Date:  1997-03

2.  Radionuclide transformations. Energy and intensity of emissions. Report of a Task Group of Committee 2 of the International Commission on Radiological Protection on data used in ICRP Publication 30.

Authors: 
Journal:  Ann ICRP       Date:  1983

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 4.  Radioembolization of liver tumors with yttrium-90 microspheres.

Authors:  Hojjat Ahmadzadehfar; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Semin Nucl Med       Date:  2010-03       Impact factor: 4.446

5.  Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma.

Authors:  Bruno Sangro; Jose I Bilbao; Jose Boan; Antonio Martinez-Cuesta; Alberto Benito; Javier Rodriguez; Angel Panizo; Belen Gil; Mercedes Inarrairaegui; Ignacio Herrero; Jorge Quiroga; Jesus Prieto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-14       Impact factor: 7.038

6.  SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.

Authors:  Monia E Hamami; Thorsten D Poeppel; Stephan Müller; Till Heusner; Andreas Bockisch; Philipp Hilgard; Gerald Antoch
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

7.  First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation.

Authors:  Etienne Garin; Yan Rolland; Eveline Boucher; Valérie Ardisson; Sophie Laffont; Karim Boudjema; Patrick Bourguet; Jean-Luc Raoul
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

8.  Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.

Authors:  Patrick Flamen; Bruno Vanderlinden; Philippe Delatte; Ghanem Ghanem; Lieveke Ameye; Marc Van Den Eynde; Alain Hendlisz
Journal:  Phys Med Biol       Date:  2008-10-31       Impact factor: 3.609

9.  Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.

Authors:  Andrew Kennedy; Subir Nag; Riad Salem; Ravi Murthy; Alexander J McEwan; Charles Nutting; Al Benson; Joseph Espat; Jose Ignacio Bilbao; Ricky A Sharma; James P Thomas; Douglas Coldwell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

  9 in total
  13 in total

1.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  Francesco Giammarile; Lisa Bodei; Carlo Chiesa; Glenn Flux; Flavio Forrer; Françoise Kraeber-Bodere; Boudewijn Brans; Bieke Lambert; Mark Konijnenberg; Françoise Borson-Chazot; Jan Tennvall; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07       Impact factor: 9.236

Review 2.  Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma.

Authors:  Shashi B Paul; Hanish Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-05-24

3.  Feasibility of imaging 90 Y microspheres at diagnostic activity levels for hepatic radioembolization treatment planning.

Authors:  Britt Kunnen; Martijn M A Dietze; Arthur J A T Braat; Marnix G E H Lam; Max A Viergever; Hugo W A M de Jong
Journal:  Med Phys       Date:  2020-01-20       Impact factor: 4.071

4.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28

Review 5.  Radioembolization for the Treatment of Primary and Metastatic Liver Cancers.

Authors:  Eun Jeong Lee; Hyun Woo Chung; Joon-Hyung Jo; Young So
Journal:  Nucl Med Mol Imaging       Date:  2019-11-08

6.  High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner.

Authors:  Heying Duan; Mohamed H Khalaf; Valentina Ferri; Lucia Baratto; Shyam M Srinivas; Daniel Y Sze; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-14       Impact factor: 9.236

7.  Yttrium-90-labeled microsphere tracking during liver selective internal radiotherapy by bremsstrahlung pinhole SPECT: feasibility study and evaluation in an abdominal phantom.

Authors:  Stephan Walrand; Michel Hesse; Georges Demonceau; Stanislas Pauwels; François Jamar
Journal:  EJNMMI Res       Date:  2011-12-02       Impact factor: 3.138

8.  The relation between perfusion pattern of hepatic artery perfusion scintigraphy and response to y-90 microsphere therapy.

Authors:  Bilge Volkan-Salancı; Murat Fani Bozkurt; Bora Peynircioğlu; Barbaros Cil; Omer Uğur
Journal:  Mol Imaging Radionucl Ther       Date:  2013-12-10

9.  The effect of selective internal radiation therapy with yttrium-90 resin microspheres on lung carbon monoxide diffusion capacity.

Authors:  Tunc Ones; Emel Eryuksel; Feyyaz Baltacioglu; Berrin Ceyhan; Tanju Yusuf Erdil
Journal:  EJNMMI Res       Date:  2017-12-29       Impact factor: 3.138

10.  Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.

Authors:  Beatrijs A Seinstra; Luc Defreyne; Bieke Lambert; Marnix G E H Lam; Helena M Verkooijen; Karel J van Erpecum; Bart van Hoek; Arian R van Erkel; Minneke J Coenraad; Imad Al Younis; Hans van Vlierberghe; Maurice A A J van den Bosch
Journal:  Trials       Date:  2012-08-23       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.